Literature DB >> 2282990

Evidence for rapid selection and deletion of HIV-1 subpopulations in vivo by V3-specific neutralizing antibody: a model of humoral-associated selection.

P Nara1, L Smit, N Dunlop, W Hatch, M Merges, D Waters, J Kelliher, W Krone, J Goudsmit.   

Abstract

Emergence in two chimpanzees of HIV-1 HTLV-IIIB variants resistant to neutralization by the pre-existing antibody is described. Viruses isolated from the HTLV-IIIB gp120 vaccinated and challenged animal were more resistant to neutralization, had more heterogenic genomes and showed more pronounced antigenic drift as determined by serotypic neutralization analysis than viruses isolated from the naive infected animal, indicating immune pressure as the selective mechanism. The earliest selecting antibody population detected in the chimpanzees appeared to be conformationally dependent. This was demonstrated by its ability to neutralize only the most replication-competent sub-populations of the HTLV-IIIB inoculum strain, yet was found to bind a HTLV-IIIB common nonapeptide (IQRGPGRAF) derived from the gp120 isolate-specific 3rd variable domain (V3) also known to induce isolate-specific neutralization in multiple species. Each of the recovered isolates had become resistant to neutralization by both a monoclonal (0.5 beta) and polyclonal HTLV-IIIB gp120 V3-specific antibody by as much as 16 to 256-fold. Amplification of the V3 coding sequence by polymerase chain reaction and subsequent sequence analysis of the neutralization-resistant variants obtained from in vivo infected animals indicated that resistance to neutralization was conferred by changes outside the direct binding site for the selective neutralizing antibody. Further studies indicated that apparent neutralization-resistant variants, yielded after in vitro passage through chimpanzee and human peripheral blood mononuclear cell cultures void of HIV-specific antibody, result from the homogenic amplification of the more replication competent sub-population pre-existing in the original viral stock. These faster replicating sub-populations appear to dominate initially and therefore are the initial prime targets recognized by the chimpanzee humoral immune system upon infection in vivo and thus eliminated. The described finding of virus escape due to a conformationally-induced flexibility of the major neutralization epitope termed "conformational-V3 hypervariability", coupled to the known primary amino acid hypervariability of this epitope (V3) termed "linear-V3 hypervariability", may be all that is required by the virus to survive in an otherwise effective humoral immune system.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2282990

Source DB:  PubMed          Journal:  Dev Biol Stand        ISSN: 0301-5149


  7 in total

Review 1.  Clinical use of quantitative molecular methods in studying human immunodeficiency virus type 1 infection.

Authors:  M Clementi; S Menzo; P Bagnarelli; A Valenza; S Paolucci; R Sampaolesi; A Manzin; P E Varaldo
Journal:  Clin Microbiol Rev       Date:  1996-04       Impact factor: 26.132

2.  Change in tropism upon immune escape by human immunodeficiency virus.

Authors:  A McKnight; R A Weiss; C Shotton; Y Takeuchi; H Hoshino; P R Clapham
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

3.  Ability of the V3 loop of simian immunodeficiency virus to serve as a target for antibody-mediated neutralization: correlation of neutralization sensitivity, growth in macrophages, and decreased dependence on CD4.

Authors:  R E Means; T Matthews; J A Hoxie; M H Malim; T Kodama; R C Desrosiers
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

4.  Antibodies of symptomatic human immunodeficiency virus type 1-infected individuals are directed to the V3 domain of noninfectious and not of infectious virions present in autologous serum.

Authors:  M Schreiber; H Petersen; C Wachsmuth; H Müller; F T Hufert; H Schmitz
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

5.  Adaptive mutations in a human immunodeficiency virus type 1 envelope protein with a truncated V3 loop restore function by improving interactions with CD4.

Authors:  Caroline Agrawal-Gamse; Fang-Hua Lee; Beth Haggarty; Andrea P O Jordan; Yanjie Yi; Benhur Lee; Ronald G Collman; James A Hoxie; Robert W Doms; Meg M Laakso
Journal:  J Virol       Date:  2009-08-19       Impact factor: 5.103

6.  Human immunodeficiency virus type 1 envelope gene structure and diversity in vivo and after cocultivation in vitro.

Authors:  K Kusumi; B Conway; S Cunningham; A Berson; C Evans; A K Iversen; D Colvin; M V Gallo; S Coutre; E G Shpaer
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

7.  Human plasma enhances the infectivity of primary human immunodeficiency virus type 1 isolates in peripheral blood mononuclear cells and monocyte-derived macrophages.

Authors:  S C Wu; J L Spouge; S R Conley; W P Tsai; M J Merges; P L Nara
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.